Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade

Shares of Alumis Inc. (NASDAQ:ALMS) dropped 11.5% on Monday after HC Wainwright lowered their price target on the stock from $40.00 to $25.00. HC Wainwright currently has a buy rating on the stock. Alumis traded as low as $22.13 and last traded at $21.9510. Approximately 1,630,604 shares were traded during trading, a decline of 47% from the average daily volume of 3,057,718 shares. The stock had previously closed at $24.80.

Several other equities analysts also recently commented on ALMS. Leerink Partners increased their target price on Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday, January 6th. Guggenheim upped their price objective on Alumis from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Raymond James Financial initiated coverage on shares of Alumis in a report on Tuesday, March 10th. They issued a “strong-buy” rating and a $46.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Finally, Loop Capital set a $37.00 target price on shares of Alumis in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.60.

Insiders Place Their Bets

In other Alumis news, Director Srinivas Akkaraju purchased 588,235 shares of the company’s stock in a transaction on Friday, January 9th. The shares were purchased at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the purchase, the director owned 1,853,488 shares in the company, valued at $31,509,296. This represents a 46.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Foresite Capital Management Vi purchased 411,764 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the insider owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This trade represents a 7.78% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 1,823,527 shares of company stock worth $30,999,959 in the last quarter. 40.70% of the stock is currently owned by company insiders.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target sharply to $55 and kept an “outperform” rating, signaling substantial upside vs. the current share level and supporting buying interest. Article Title
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating with a $38 price target, reiterating institutional conviction and adding support for bullish flows. Article Title
• Positive Sentiment: Morgan Stanley (via a TipRanks summary) maintained a Buy rating and $38 target, citing strong Phase‑3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a clinical/data catalyst that underpins upside expectations. Article Title
• Neutral Sentiment: HC Wainwright issued FY2027 EPS estimates of ($3.37) and kept a “Buy” rating with a $25 target — the EPS forecast is materially less negative than the consensus (-$8.51), which could be read as relatively constructive, but the figure is still negative and reflects ongoing cash burn/near‑term losses.
• Negative Sentiment: HC Wainwright cut its prior price target from $40 to $25 while retaining a buy rating, a mixed signal that reduces some upside expectations and may have pressured shorter‑term sentiment. Article Title
• Negative Sentiment: On 3/30 ALMS fell roughly 11% amid profit‑taking after a ~239% yearly gain; technical selling and traders locking gains were cited as drivers of the pullback. That short‑term volatility can amplify moves when headlines on ratings/targets hit the tape. Why Is Alumis Stock Falling Monday?

Institutional Trading of Alumis

Several hedge funds have recently modified their holdings of ALMS. Russell Investments Group Ltd. lifted its position in shares of Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in Alumis by 199.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after purchasing an additional 7,165 shares during the period. New York State Common Retirement Fund increased its stake in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after purchasing an additional 7,467 shares in the last quarter. CWM LLC increased its stake in Alumis by 1,028.7% in the third quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after purchasing an additional 9,464 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares during the period.

Alumis Price Performance

The stock has a market cap of $2.80 billion, a price-to-earnings ratio of -7.20 and a beta of -2.15. The firm’s fifty day moving average price is $26.42 and its two-hundred day moving average price is $14.79.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. The firm had revenue of $1.93 million during the quarter, compared to analyst estimates of $2.75 million. On average, equities research analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.